Skip to the stories
Wednesday, 18 November 2026
Saved

Next edition

9:21

Headlines

Medical Science

CAR T cell therapy analysis reveals high inflammation but low mortality

A systematic review of 21 clinical trials showed that cytokine release syndrome occurred in most cancer patients receiving CAR-T therapy, while treatment-related mortality remained low.

FTMQ Health, written by our newsroom0 views

Share

A meta-analysis of 21 clinical trials has found that chimeric antigen receptor T-cell therapy carries high rates of inflammation but low overall mortality, Bioengineer.org reported. Researchers analyzed safety outcomes across 1,692 cancer patients to profile the major toxicities associated with the treatment. The findings were published in the journal Frontiers in Oncology. [1]

According to Bioengineer.org, cytokine release syndrome occurred in 77.6 percent of the treated patients. Despite the high rate of inflammation, the treatment-related mortality rate among the participants was 4.6 percent. [1]

The study was led by Dr. Khawaja Haider of Sulaiman Al Rajhi University alongside researchers from the University of California, Irvine, Bioengineer.org reported. Chimeric antigen receptor T cells are engineered proteins designed to give T cells the ability to target a specific antigen by combining antigen-binding and T cell activating functions into a single receptor. [1][7]

Inflammation is a biological defence response of body tissues that can be triggered by pathogens, physical trauma, or damaged tissues. As FTMQ Health reported earlier, systematic reviews of clinical trial data provide critical insights into treatment toxicity and adverse event risks across human patient populations. [8][10]

Share

In short

  • A meta-analysis of 21 clinical trials reviewed safety data from 1,692 cancer patients.
  • Cytokine release syndrome occurred in 77.6 percent of patients treated with CAR-T cell therapy.
  • Treatment-related mortality across the analyzed CAR-T clinical trials was 4.6 percent.
  • The research was led by Dr. Khawaja Haider of Sulaiman Al Rajhi University and scientists at UC Irvine.

Sources

Every paragraph above points to the numbered items it rests on. Read the originals here.

  1. [1]CAR-T Therapy Clinical Trials Reveal High Inflammation Rates but Low MortalityBioengineer.org, 6h ago (the report this story comes from)
  2. [2]Can Patients Afford the Costs of Cancer Clinical Trials?Medscape, 18h ago
  3. [3]Can Lifting Weights Help With Depression? What 80 Clinical Trials FoundParriva, 1d ago
  4. [4]Adagene and City of Hope Open Clinical Trial to Test New Therapy for Patients with Hard-to-Treat Colorectal CancerMacau Business, 14h ago
  5. [5]City of Hope and Adagene Open Clinical Trial to Test New Therapy for Patients with Hard-to-Treat Colorectal CancerBusiness Wire, 15h ago
  6. [6]Adagene and City of Hope Open Clinical Trial to Test New Therapy for Patients with Hard-to-Treat Colorectal CancerGlobeNewswire, 15h ago

Background

  1. [7]CAR T cell on Wikipedia
  2. [8]Inflammation on Wikipedia
  3. [9]Infant mortality on Wikipedia
  4. [10]RIPK1 Inhibitors Match Placebo Safety in Human Clinical Trials FTMQ Health, 2d ago

Our newsroom writes these reports with the help of software, from the 10 sources listed and nothing else, and checks them against those sources. Facts can still be wrong or move on; the originals are the record. Spotted a mistake? Write to daniel@monsterkong.com.

Earlier reports of ours on the same people and subjects.

More in Medical Science

Get the day in one email

Reports like this one, the top news of the last 24 hours, every morning. Free, one email a day; readers can comment under every report.

By signing up you agree to our terms and privacy policy. Unsubscribe any time.

Comments

Loading

Join the conversation

Comments are open to readers of our daily email: the top news of the last 24 hours, every morning, free. Sign up and the comment box opens.

Already on the list? Enter the same address and we will send a sign-in link.

By signing up you agree to our terms and privacy policy. Unsubscribe any time.